Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 283-294

  Suzuki, Yasuo ^a   Motoya, Satoshi ^b   Hanai, Hiroyuki ^c   Matsumoto, Takayuki ^d   Hibi, Toshifumi ^e   Robinson, Anne M ^f   Mostafa, Nael M ^f   Chao, Jingdong ^f   Arora, Vipin ^f   Camez, Anne ^f   Thakkar, Roopal B ^f   Watanabe, Mamoru ^g  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c Hamamatsu South Hospital   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e KITASATO INSTITUTE HOSPITAL   (Japan)

^f ABBVIE INC   (United States)

^g TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adalimumab; Clinical remission; Japan; Mucosal healing; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; PLACEBO; PREDNISOLONE;

ADULT; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; DESCENDING COLON; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL BIOPSY; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INJECTION SITE REACTION; JAPANESE; LIVER DISEASE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPPORTUNISTIC INFECTION; PANCOLITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896718706     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0922-y     Document Type: Article

References (24)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29.
2. Sands BE, Kaplan GG. The role of TNFα in ulcerative colitis. J Clin Pharmacol. 2007;47:930-41.
3. Hamilton MJ, Snapper SB, Blumberg RS. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. 2012;47:1-8.
4. Arimura Y, Isshiki H, Onodera K, et al. Characteristics of Japanese inflammatory bowel disease susceptibility loci. J Gastroenterol. 2013 (Epub ahead of print).
5. Kuwahara E, Asakura K, Nishiwaki Y, et al. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 2012;47:961-8.
6. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-7.
7. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(257-65):e3.
8. Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013;19:1700-9.
9. Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol. 2009;44:659-65.
10. Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012;6:160-73.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-9.
12. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-10.
13. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013 (Epub ahead of print).
14. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-21.
15. Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
16. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33.
17. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
18. Humira [package insert]. North Chicago, IL: AbbVie Inc; 2013.
19. Miyasaka N, the CHANGE study investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252-62.
20. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91.
21. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthr Rheum. 2006;55:19-26.
22. Humira [Japanese package insert]. Tokyo, Japan: AbbVie GK and Eisai Co, Ltd; 2013.
23. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
24. Sandborn WJ, Colombel J-F, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37:204-13.